The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Open accessAbstract
Pathological expression of human ErbB-2 protein, also known as HER-2, is common in many types of cancer. ErbB-2 is a member of the EGF receptor tyrosine kinase family and has been rigorously studied as a signaling molecule on the cell membrane. Here, we report that ErbB-2 is also expressed in the nucleus in cultured cells as well as primary tumor tissues. Nuclear ErbB-2 was found to associate with multiple genomic targets in vivo, including the cyclooxygenase enzyme COX-2 gene promoter. ErbB-2 forms a complex at a specific nucleotide sequence of the COX-2 promoter and is able to stimulate its transcription. This study demonstrates the presence of ErbB-2 in the nucleus and identifies the function of ErbB-2 as a transcriptional regulator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 3×
“The proto-oncogene ErbB-2 encodes a 185 kDa tyrosine kinase receptor that belongs to the epithelial growth factor receptor Elevated ErbB-2 expression is associated with promoted proliferation potential, enhanced resistance to apoptotic stimuli, and(EGFR) family (Yarden and Sliwkowski, 2001).”
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Self-citationγ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimaki, A. P., Sivula, A., Lundin, J. E., Lundin, M., Salminen, T. M., Haglund, C. H., Joensuu, H., & Isola, J. J. (2002) · PubMed · Cited by 780
Cited by
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
Kalyankrishna, S., & Grandis, J. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8306 · Cited by 747
Derailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Self-citationThe role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Self-citationProtein localization in disease and therapy
Hung, M.-C., & Link, W. (2011) · Journal of Cell Science · doi:10.1242/jcs.089110 · Cited by 431
Self-citationThe EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
Lo, H.-W., & Hung, M.-C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602941 · Cited by 323
Self-citationTyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Self-citationNuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 313
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
Self-citationDesai, S. J., Prickril, B., & Rasooly, A. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1446091 · Cited by 274
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Self-citationBiosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Hartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137
Harter, P. N., Zinke, J., Scholz, A., Tichy, J., Zachskorn, C., Kvasnicka, H. M., Goeppert, B., Delloye-Bourgeois, C., Hattingen, E., Senft, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092311 · Cited by 41
Metadata
- Authors
- Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., Giri, D. K., & Hung, M.-C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 6
- Issue
- 3
- Pages
- 251-261
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2023648132
- Cited by
- 305
- References
- 44
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.